Article

Low doses of alcohol substantially decrease glucose metabolism in the human brain.

National Institute on Drug Abuse, 6001 Executive Blvd., Room 5274, Bethesda, MD 20892, USA.
NeuroImage (Impact Factor: 6.13). 02/2006; 29(1):295-301. DOI: 10.1016/j.neuroimage.2005.07.004
Source: PubMed

ABSTRACT Moderate doses of alcohol decrease glucose metabolism in the human brain, which has been interpreted to reflect alcohol-induced decreases in brain activity. Here, we measure the effects of two relatively low doses of alcohol (0.25 g/kg and 0.5 g/kg, or 5 to 10 mM in total body H2O) on glucose metabolism in the human brain. Twenty healthy control subjects were tested using positron emission tomography (PET) and FDG after placebo and after acute oral administration of either 0.25 g/kg, or 0.5 g/kg of alcohol, administered over 40 min. Both doses of alcohol significantly decreased whole-brain glucose metabolism (10% and 23% respectively). The responses differed between doses; whereas the 0.25 g/kg dose predominantly reduced metabolism in cortical regions, the 0.5 g/kg dose reduced metabolism in cortical as well as subcortical regions (i.e. cerebellum, mesencephalon, basal ganglia and thalamus). These doses of alcohol did not significantly change the scores in cognitive performance, which contrasts with our previous results showing that a 13% reduction in brain metabolism by lorazepam was associated with significant impairment in performance on the same battery of cognitive tests. This seemingly paradoxical finding raises the possibility that the large brain metabolic decrements during alcohol intoxication could reflect a shift in the substrate for energy utilization, particularly in light of new evidence that blood-borne acetate, which is markedly increased during intoxication, is a substrate for energy production by the brain.

Full-text

Available from: George Kunos, Apr 01, 2015
1 Bookmark
 · 
105 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ethanol is a known neuromodulatory agent with reported actions at a range of neurotransmitter receptors. Here, we measured the effect of alcohol on metabolism of [3-(13) C]pyruvate in the adult Guinea pig brain cortical tissue slice and compared the outcomes to those from a library of ligands active in the GABAergic system as well as studying the metabolic fate of [1,2-(13) C]ethanol. Analyses of metabolic profile clusters suggests that the significant reductions in metabolism induced by ethanol (10, 30 and 60 mM) are via action at neurotransmitter receptors, particularly α4β3δ receptors, while very low concentrations of ethanol may produce metabolic responses due to release of GABA via GAT1 and the subsequent interaction of this GABA with local α5- or α1-containing GABA(A)R. There was no measureable metabolism of [1,2-(13) C]ethanol with no significant incorporation of (13) C from [1,2-(13) C]ethanol into any measured metabolite above natural abundance, although there were measurable effects on total metabolite sizes similar to those seen with unlabeled ethanol. This article is protected by copyright. All rights reserved.
    Journal of Neurochemistry 04/2014; 129:304-314.. DOI:10.1111/jnc.12634 · 4.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neuroimaging, including PET, MRI, and MRS, is a powerful approach to the study of brain function. This article reviews neuroimaging findings related to alcohol and other drugs of abuse that have been published since 2011. Uses of neuroimaging are to characterize patients to determine who will fare better in treatment and to investigate the reasons underlying the effect on outcomes. Neuroimaging is also used to characterize the acute and chronic effects of substances on the brain and how those effects are related to dependence, relapse, and other drug effects. The data can be used to provide encouraging information for patients, as several studies have shown that long-term abstinence is associated with at least partial normalization of neurological abnormalities.
    03/2014; 1(1). DOI:10.1007/s40473-013-0005-7
  • [Show abstract] [Hide abstract]
    ABSTRACT: Brain 18F-FDG PET allows the in vivo study of cerebral glucose metabolism, reflecting neuronal and synaptic activity. 18F-FDG PET has been extensively used to detect metabolic alterations in several neurological diseases vs. normal aging. However, healthy subjects exhibit variants of 18F-FDG distribution, especially as associated with aging. 18F-FDG uptake is usually homogeneous and symmetrical, but areas of slightly higher activity are observed in basal ganglia, frontal eye fields, posterior cingulate cortex and visual cortex. On the contrary, relatively lower metabolic activity is observed in medial temporal cortex. This review will focus on 18F-FDG PET findings in so-called normal brain aging, and in particular on metabolic differences occurring with aging and as a function of people's gender. The effect of different substances, medications and therapy procedures will be discussed, as well as common artifacts.
    PET Clinics 04/2014; 9(2):129-140. DOI:10.1016/j.cpet.2013.10.006